Tesamorelin is a prescription peptide used to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Its approved products, Egrifta WR and Egrifta SV, are not general weight-loss medicines. That distinction is easy to miss when a study’s reduction in deep abdominal fat gets repeated as a promise to lose the same percentage of body weight. [1] [2]
Check who received treatment, which fat compartment was measured and how long the trial lasted. A change in visceral fat isn’t the same outcome as a change in body weight.
Related dosage pages: For vial-specific concentration, reconstitution, and measurement examples, see Tesamorelin (5 mg Vial) Dosage Protocol, Tesamorelin (10 mg Vial) Dosage Protocol, and Tesamorelin (20 mg Vial) Dosage Protocol. Each linked protocol remains a separate reference because vial strength changes concentration and syringe-unit calculations.
How tesamorelin works
Tesamorelin is a synthetic analog of growth hormone-releasing factor. It stimulates growth hormone release from the pituitary, which also increases IGF-1. It does not work through the GLP-1 pathway used by drugs such as semaglutide. [1]
The fat under the skin is called subcutaneous fat. Visceral fat sits deeper, around abdominal organs. In the pivotal tesamorelin trial, researchers measured visceral adipose tissue by CT, not just weight on a bathroom scale or the appearance of someone’s stomach. [3]
How much visceral fat did the trials reduce?
A 26-week randomized trial enrolled 412 adults with HIV and abdominal fat accumulation; 86% were men. The CT measure of visceral fat fell by 15.2% with tesamorelin and rose by 5.0% with placebo. These were average changes from each group’s baseline, not a guarantee for every participant. [3]
| Finding | What it does and does not show |
|---|---|
| 15.2% reduction in visceral fat 26-week HIV trial. |
A reduction in the CT measure of deep abdominal fat, not 15.2% weight loss or removal of all abdominal fat. [3] |
| Benefit with continued treatment Extension through 52 weeks. |
Visceral fat reduction was maintained with continued treatment; fat reaccumulated after switching to placebo. This was not permanent fat removal. [4] |
| Research outside the approved indication 60 adults with abdominal obesity and reduced GH secretion. |
A 12-month study found a favorable visceral-fat change. Its selected population and small size do not establish suitability for everyone with obesity. [5] |
| Liver-fat research 2024 analysis in people with HIV and fatty liver. |
Results in a subgroup receiving integrase-inhibitor treatment were promising, but do not establish an approved treatment for fatty liver in the general population. [6] |
The original trial also reported improvements in triglycerides and some other lipid measures. Those laboratory changes are not proof that tesamorelin prevents heart attacks. Its label says long-term cardiovascular safety has not been established. [3] [1]
Quick check: does “15% less visceral fat” mean “15% less body weight”?
No. Visceral fat is one part of body composition. A change in its CT measurement cannot be read as the same percentage change in total body weight. The pivotal trial’s outcome and the bathroom scale answer different questions.
Can tesamorelin be used for general weight loss?
The approved indication is excess abdominal fat in adults with HIV-associated lipodystrophy. The labeling describes a weight-neutral effect and says tesamorelin is not indicated for weight-loss management. An online “fat-loss peptide” label is broader than the actual approval. [1]
There is research beyond that indication. In the 60-person obesity trial, participants had reduced growth hormone secretion as well as abdominal obesity. After 12 months, visceral-fat area decreased by 16 cm² in the tesamorelin group and increased by 19 cm² with placebo. Subcutaneous fat did not significantly change. This is a useful research signal, not a universal obesity treatment result. [5]
The liver-fat literature also needs careful reading. The 2024 report analyzed 38 participants receiving integrase inhibitors within a larger HIV/fatty-liver trial; 31 completed follow-up. Improvements in liver fat and visceral fat in this subgroup cannot simply be applied to someone without HIV or with a different liver condition. [6]
Egrifta WR and Egrifta SV are not interchangeable
“Tesamorelin” names the active drug, not one universal preparation. Current Egrifta formulations differ in vial strength, prescribed dose and preparation requirements. Follow the instructions supplied with the exact prescription, not an older study or another product’s instructions. [1] [2]
| Product | Important difference |
|---|---|
| Egrifta WR | A multidose vial prepared once weekly, with a separate dose administered each day. Weekly preparation does not mean a weekly injection. [1] |
| Egrifta SV | A single-dose vial prepared for immediate use each day. Its dose, preparation and handling instructions differ from WR. [2] |
| Research-labeled or compounded products | Do not assume equivalence to either approved product. Compounded finished medicines are not FDA-approved; the same ingredient name does not establish matching quality or instructions. [8] |
A pharmacist or prescriber should demonstrate preparation and confirm the product-specific instructions. If the name on the prescription changes, check the instructions again rather than carrying over the previous routine. MedlinePlus specifically recommends obtaining training before the first injection. [7]
Side effects and monitoring
Reported reactions include injection-site irritation, joint or muscle pain, swelling and symptoms such as hand tingling or wrist discomfort. Contact the treating clinician about persistent or troublesome effects. Seek urgent care for breathing difficulty, throat or facial swelling, fainting or other signs of a serious allergic reaction. [7]
Safety monitoring matters even when a study reports an average improvement in body composition. The Egrifta SV label calls for monitoring glucose and IGF-1. Across its 26-week trial data, new diabetes meeting the specified HbA1c threshold occurred in 5% of tesamorelin recipients versus 1% receiving placebo. A favorable average glucose result in one study does not erase that risk. [2]
Contraindications include pregnancy, active malignancy, certain disruptions of the hypothalamic-pituitary axis and known hypersensitivity. A history of treated cancer also requires careful evaluation. People with diabetes need particular attention to glucose and diabetic-retinopathy monitoring. [2]
Before treatment, the clinician needs a full medication list and history, including pituitary disease or procedures, head radiation or trauma, cancer, diabetes and pregnancy plans. This is not a decision that a body-fat photograph or a single IGF-1 value can settle. [7]
Frequently asked questions
How long before results appear?
The pivotal comparison measured visceral fat at 26 weeks, and extension research followed treatment to 52 weeks. Those time points do not promise that an individual will notice a visible change in a particular week. Clinicians assess response and whether continued treatment is appropriate. [3] [4]
Does the fat come back after stopping?
In the extension study, participants switched from tesamorelin to placebo regained visceral fat. That makes “one cycle permanently removes belly fat” a poor description of the evidence. It also means long-term benefit, burden and monitoring need to be discussed together. [4]
Is tesamorelin like Ozempic?
No. They have different mechanisms and approved uses. Tesamorelin’s HIV-associated lipodystrophy indication should not be confused with semaglutide’s product-specific diabetes and weight-management indications. See the separate Semaglutide guide for that evidence.
Bottom line: Tesamorelin has clinical evidence for reducing visceral fat in a defined medical setting. It is not a general-purpose weight-loss shortcut, and a smaller visceral-fat measurement is not the same as proven cardiovascular protection. A qualified clinician should confirm the indication, exact formulation and monitoring plan.
Related dosage protocols and research
Explore related research, dosage references and guides below. Vial strengths have separate references because concentration and syringe-unit calculations differ. A comparison does not mean the compounds are interchangeable.
Matching dosage protocols
Related protocols and comparisons
Further research context
References
- FDA. Egrifta WR prescribing information.
- DailyMed. Egrifta SV prescribing information.
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007.
- Falutz J, et al. Long-term safety and effects of tesamorelin in HIV-associated abdominal fat accumulation. AIDS. 2008.
- Makimura H, et al. Effects of tesamorelin in abdominally obese adults with reduced growth hormone secretion. J Clin Endocrinol Metab. 2012.
- Tesamorelin effects on visceral and liver fat in people with HIV receiving integrase inhibitors. 2024 subgroup analysis.
- MedlinePlus. Tesamorelin injection: patient drug information.
- FDA. Compounding and the FDA: Questions and Answers.